Open AccessHydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Author(s) -
Ruanne V. Barnabas,
Elizabeth R. Brown,
Anna Bershteyn,
Helen C. Stankiewicz Karita,
Christine Johnston,
Lorna E. Thorpe,
Angelica C Kottkamp,
Kathleen M. Neuzil,
Miriam K. Laufer,
Meagan E. Deming,
Michael K. PaascheOrlow,
Patricia Kissinger,
Alfred Luk,
Kristopher Paolino,
Raphael J. Landovitz,
Risa M. Hoffman,
Torin T Schaafsma,
Meighan Krows,
Katherine K. Thomas,
Susan Morrison,
Harald S. Haugen,
Lara Kidoguchi,
Mark H. Wener,
Alexander L. Greninger,
Meei Li Huang,
Keith R. Jerome,
Anna Wald,
Connie Celum,
Helen Y. Chu,
Jared M. Baeten
Publication year - 2021
Publication title -
annals of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.839
H-Index - 390
eISSN - 1539-3704
pISSN - 0003-4819
DOI - 10.7326/m20-6519
Subject(s) - hydroxychloroquine , medicine , placebo , hazard ratio , randomized controlled trial , pre exposure prophylaxis , coronavirus , covid-19 , immunology , disease , pathology , human immunodeficiency virus (hiv) , confidence interval , alternative medicine , syphilis , men who have sex with men , infectious disease (medical specialty)
Effective prevention against coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently limited to nonpharmaceutical strategies. Laboratory and observational data suggested that hydroxychloroquine had biological activity against SARS-CoV-2, potentially permitting its use for prevention.